Castle Biosciences, Inc. (CSTL) reported $66.12 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 72.5%. EPS of -$0.10 for the same period compares to -$0.78 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $51.32 million, representing a surprise of +28.85%. The company delivered an EPS surprise of +88.10%, with the consensus EPS estimate being -$0.84.While investors scrutinize revenue and earnings changes year-over-year and how they ...